The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: A meta-analysis and commentary on published studies

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2166-2174

  Ziakas, Panayiotis D ^a   Poulou, Loukia S ^b,c   Voulgarelis, Michael ^a   Thanos, Loukas ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c Agii Anargyri General Oncology Hospital   (Greece)

Author keywords

early; Hodgkin lymphoma; interim; meta analysis; PET; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL DECISION MAKING; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84865779055     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.685730     Document Type: Article

References (60)

1. Johnson PW, Sydes MR, Hancock BW, et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010;28:3352-3359.
2. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-652. (Pubitemid 38297098)
3. Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011;153:358-363.
4. Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:451-457.
5. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
6. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803-808.
7. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854.
8. Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. Eur J Radiol 2009;70:499-506.
9. Poulou LS, T anos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging 2010;37:156-162.
10. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-f uorodeoxyglucose positron emission tomography in response assessment before highdose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010;15:750-759.
11. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-f uorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-1914.
12. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50:257-260.
13. Juweid ME, Stroobants S, Hoekstra OS, et al.; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578. (Pubitemid 350002965)
14. Cheson BD, Pf stner B, Juweid ME, et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
15. Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171-2180.
16. Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging 2010;37:1821-1823.
17. Barrington S F, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824-1833.
18. Whiting P F, Rutjes AW, Westwood ME, et al.; the QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536.
19. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specif city produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-990. (Pubitemid 41316441)
20. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol 2006;18:271-281. (Pubitemid 44148267)
21. Grimes DA, Schulz KF. Ref ning clinical diagnosis with likelihood ratios. Lancet 2005;365:1500-1505. (Pubitemid 40591696)
22. Higgins JP, T ompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560. (Pubitemid 37088507)
23. Harbord RM, Deeks JJ, Egger M, et al. A unif cation of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-251. (Pubitemid 46569586)
24. Lau J, Ioannidis J P, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826. (Pubitemid 27465551)
25. O'Rourke K. Mixed means and medians: a unif ed approach to deal with disparate outcome summaries. Presented at 4th Symposium on Systematic Reviews: Pushing the Boundaries. 2002. Oxford: p 49.
26. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011;259:117-126.
27. Dwamena B. MIDAS: metaanalytical integration of diagnostic accuracy studies in Stata. 6th North American Stata Users Group Meeting, Boston, MA, August 2007. Available from: http://sitemaker. umich.edu/metadiagnosis/midas- home
28. Dann EJ, Blumenfeld Z, Bar-Shalom R, et al. A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are ef ective and female fertility is preserved. Am J Hematol 2012;87:32-36.
29. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim (18)F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012;39:4-12.
30. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-f uoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 2012;53:64-70.
31. Luminari S, Cesaretti M, Tomasello C, et al. Use of 2-[18F]f uoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. Leuk Lymphoma 2011;52:1689-1696.
32. Straus DJ, Johnson JL, LaCasce AS, et al.; Cancer and Leukemia Group B. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011;117:5314-5320.
33. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064-1071.
34. Gallamini A, Patti C, Viviani S, et al.; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensif cation with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551-560.
35. Furth C, Amthauer H, Hautzel HJ, et al. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011;22:1198-1203.
36. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011;22:910-915.
37. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010;51:1337-1343.
38. Dann EJ, Bar-Shalom R, Tamir A, et al. A functional dynamic scoring model to elucidate the signif cance of post-induction interim f uorine-18-f uorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. Haematologica 2010; 95:1198-1206.
39. Furth C, Stef en IG, Amthauer H, et al. Early and late therapy response assessment with [18F]f uorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009;27:4385-4391.
40. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an ef ective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010;21:126-132.
41. Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic signif cance of mid-and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848-1853.
42. Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270-1274.
43. Paolini R, Rampin L, Rodella E, et al. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study. Nucl Med Rev Cent East Eur 2007;10:87-90. (Pubitemid 351266290)
44. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]f uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
45. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678-2687. (Pubitemid 44845624)
46. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905-909. (Pubitemid 46220633)
47. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006;85:759-767. (Pubitemid 44377874)
48. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296-1300. (Pubitemid 44288221)
49. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
50. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59. (Pubitemid 43053523)
51. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168. (Pubitemid 41418320)
52. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92. (Pubitemid 38181398)
53. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004;31:22-28. (Pubitemid 38133537)
54. Slabý J, Bělohlávek O, Táborsk á K, et al. [Predictive features of positron emission tomography after two cycles of induction therapy in malignant lymphoma]. Cas Lek Cesk 2002;141:312-315.
55. Ziakas PD, Poulou LS. Improving outcome after positive interim PET in advanced Hodgkin's disease: reality vs expectation. Eur J Nucl Med Mol Imaging 2008;35:1573-1575.
56. Gallamini A, O'Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma:8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma 2011;52:583-586.
57. Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
58. Lurati Buse GA, Koller MT, Grapow M, et al. The prognostic value of troponin release after adult cardiac surgery-a meta-analysis. Eur J Cardiothorac Surg 2010;37:399-406.
59. Whiting P, Rutjes AW, Reitsma JB, et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202. (Pubitemid 38155650)
60. Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 2007;100:193-201. (Pubitemid 47061687)